UNICREDIT BANK/PUT/MODERNA/200/0.1/18.06.25 | Real-time BOERSE MUENCHEN 15:41:39 2024-05-22 EDT | ||
| 4.99 EUR | -16.56% |
|
| Current month | -40.74% | ||
| 1 month | -44.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 4.99 | -16.56% |
| 24-05-21 | 5.98 | -1.81% |
| 24-05-20 | 6.09 | -8.01% |
| 24-05-17 | 6.62 | +0.46% |
| 24-05-16 | 6.59 | -4.22% |
Real-time BOERSE MUENCHEN
Last update May 22, 2024 at 03:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HC7U69 |
| ISIN | DE000HC7U698 |
| Date issued | 2023-06-30 |
| Strike | 200 $ |
| Maturity | 2025-06-18 (392 Days) |
| Parity | 10 : 1 |
| Emission price | 7.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.37 € |
|---|---|
| Lowest since issue | 4.99 € |
| Spread | 0.06 € |
| Spread % | 1.19% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- Warrant
